• Mashup Score: 7

    Despite significant gains in cancer-specific survival in recent decades, cancer remains among the most common causes of human mortality, causing ∼10 million deaths globally in 2020.1 It is thus imperative to develop new anticancer agents with more efficacious mechanisms of action, and to deploy optimal methodologies for their manufacture and distribution.

    Tweet Tweets with this article
    • Will complex, individualized therapies for cancer such as CAR-Ts be manufactured at the patients bedside in future? Our editorial in @Annals_Oncology appeared in print on 1 Jan 2022. https://t.co/ZTkSwsmETA @FAndreMD @barlesi @OncoAlert

  • Mashup Score: 8

    The landscape in immuno-oncology (I-O) has undergone profound changes since its early beginnings up through the rapid advances happening today. The current drug development pipeline consists of thousands of potential I-O therapies and therapy combinations, many of which are being evaluated in clinical trials. The efficient and successful development of these assets requires the investment in and…

    Tweet Tweets with this article
    • RT @jitcancer: New #JITC review: Immuno-oncology trends: preclinical models, biomarkers, and clinical development https://t.co/UFiW5X0N5o @…

  • Mashup Score: 0

    Le site du journal Le Soir, premier site d’information en Belgique francophone. Actu en continu, archives gratuites, galeries photos, podcast, vidéos, blogs de la rédaction, résultats sportifs, forums…

    Tweet Tweets with this article
    • The #COVID19 situation in #Belgium has become worrisome (again)... #BlackFriday #MaskUp #Thanksgiving #StaySafe https://t.co/cbySE2KcsQ